Pharma: Clinic Roundup
Monday, April 2, 2012
Shire plc, of Dublin, Ireland, said that once-daily SPD476 (MMX mesalamine) did not reduce the rate of recurrence of diverticulitis over a 2-year treatment period in a Phase III (PREVENT2) trial. It also failed to separate from placebo on its secondary endpoint. A second trial (PREVENT1) still has results pending, but the company does not intend to pursue a regulatory filing for MMX mesalamine in that indication.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.